Table 2.
Clinical outcomes and adverse event of EUS-FNB
| Variables | Total (n=75) | |
|---|---|---|
| Technical success, n (%) | 75 (100) | |
| Number of needle pass, n (range) | 2 (2-5) | |
| Two, n (%) | 44 (58.7) | |
| hree, n (%) | 27 (36.0) | |
| Four, n (%) | 3 (4.0) | |
| Five, n (%) | 1 (1.3) | |
| Biopsy | Final diagnosis | |
| Malignant | Benign | |
| Malignant | 29 | 0 |
| Benign | 1* | 44 |
| Inconclusive | 0 | 1* |
| Sensitivity | 96.7% (95% CI: 0.828-0.999) (29/30) | |
| Specificity | 97.8% (95% CI: 0.882-0.999) (44/45) | |
| Positive predictive value | 100% (29/29) | |
| Negative predictive value | 100% (44/44) | |
| Overall accuracy | 97.3% (95% CI: 0.898-0.995) (73/75) | |
| Procedure-related adverse event, n (%) | 0 | |
*Two patients were diagnosed as neuroendocrine tumor and pancreatic cancer, respectively. CI: Confidence interval